Paper
24 March 2023 Mutations of MYH7 gene and potential therapeutic target for HCM
Yi Wu
Author Affiliations +
Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 1261156 (2023) https://doi.org/10.1117/12.2669387
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom
Abstract
Hypertrophic cardiomyopathy (HCM) is a common cardiovascular disease with detectable symptoms. Clinical manifestations vary but generally include diastolic dysfunction, left ventricular outflow tract and atrial fibrillation. MYH7 is a gene that has been proved related to HCM. Various points mutations, such as R723G, V606M, V878L, H1717Q and R403Q may cause frame-shift in the gene, thus causing cardiac muscle dysfunctions. As MYH7 is a dominantly inherited gene, patients with mutated MYH7 may have different level of symptoms according to the number of mutated alleles they possess. The treatments for HCM, including traditional surgical myomectomy (SM) and alcohol septal ablation (ASA) are currently limited to alleviate clinical phenotypes. More researches and experiments on novel drugs and gene modification are ongoing.
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Yi Wu "Mutations of MYH7 gene and potential therapeutic target for HCM", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 1261156 (24 March 2023); https://doi.org/10.1117/12.2669387
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Cardiovascular disorders

Heart

Atrial fibrillation

Chest

Proteins

Muscles

Head

Back to Top